Key statistics dashboard for Monte Rosa Therapeutics, Inc. (GLUE). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers.
Stock Data
| Price | $12.65 |
| Market Cap | $1.1B |
| Enterprise Value | $1.02B |
| Beta | 1.64 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -5.82 |
| Price / Book | 2.22 |
| P/S | 37.30 |
| EV/EBITDA | -6.52 |
| EV/Sales | 35.39 |
| EV/FCF | -14.25 |
| P/FCF | -15.02 |
| Earnings Yield | -14.94% |
| FCF Yield | -6.67% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 92.94% |
| EBIT Margin | -570.80% |
| EBITDA Margin | -542.51% |
| Operating Margin | -633.04% |
| Net Margin | -560.85% |
| Return on Equity | -43.31% |
| Return on Assets | -23.15% |
| Return on Invested Capital | -28.19% |
| Return on Capital Employed | -28.90% |
Financial Health
| Current Ratio | 9.52 |
| Quick Ratio | 9.52 |
| Cash Ratio | 1.35 |
| Debt / Equity | 0.08 |
| Debt / Assets | 5.46% |
| Net Debt / EBITDA | 0.33 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.34 |
| Book Value per share | 5.69 |
| Cash per share | 7.29 |
| FCF per share | -0.84 |
| Tangible Book Value per share | 5.69 |
| Dividend per share | 0.00 |
Related companies: ARVN · AVBP · DAWN · DNA · GERN · MGTX · REPL
Explore sector: Healthcare · Biotechnology
More sections of GLUE: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks